YD Bio CEO Dr. Ethan Shen Buys 12,700 Shares

What Happened
Dr. Ethan Shen (CEO and Director of YD Bio Ltd, ticker YDES) acquired 12,700 ordinary shares on 2026-09-14. The reported weighted-average price was $3.85 per share, for a total reported purchase value of $48,895. This transaction is coded as a purchase (P), which is a direct acquisition of shares rather than a sale or option exercise.

Key Details

• Transaction date: 2026-09-14; Form 4 filed on 2026-09-16 (appears timely).
• Transaction type/code: Purchase (P) — open market or private purchase.
• Shares acquired: 12,700 at a weighted average price of $3.85; total value reported $48,895.
• Price detail (Footnote F1): The filing states the Column 4 price is a weighted average and notes transactions occurred at prices ranging from $3.67 to $3.97; the reporting person offers to provide a breakdown on request.
• Ownership structure (Footnote F2): The acquired shares are held by YD Biopharma Holding Limited, owned by E820N Assets Ltd. (BVI), which is wholly owned by The E820N Trust. Dr. Shen is settlor, protector and sole beneficiary of the Trust and is the beneficial owner of those shares.
• Shares owned after the transaction: Not specified in the provided data.

Context
Purchases by executives can be interpreted as a positive signal because they increase the insider's economic exposure, but filings do not explain motivation. This was a straightforward buy (not an option exercise, award, or gift). Footnote F1 gives a price range and weighted-average detail; Footnote F2 explains the shares are held through trust-related entities with Dr. Shen as beneficial owner.